Last Updated : May 18, 2023
Details
FilesGeneric Name:
atogepant
Project Status:
Active
Therapeutic Area:
Migraine, prevention
Manufacturer:
Allergan Inc. (an AbbVie company)
Call for patient/clinician input open:
Brand Name:
Qulipta
Project Line:
Reimbursement Review
Project Number:
SR0724-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the prevention of episodic migraine in adults with less than 15 migraine days per month who have experienced an inadequate response, intolerance or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
The prevention of episodic migraine ( 15 migraine days per month) in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 25, 2022 |
|---|---|
| Call for patient/clinician input closed | March 18, 2022 |
| Clarification: - Patient input submission received from Migraine Canada and Migraine Quebec (joint) | |
| Submission received | February 23, 2022 |
| Submission accepted | March 09, 2022 |
| Review initiated | March 10, 2022 |
| Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
| Draft CADTH review report(s) provided to sponsor for comment | March 08, 2023 |
| Deadline for sponsors comments | March 20, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | April 14, 2023 |
| Expert committee meeting (initial) | April 26, 2023 |
| Draft recommendation issued to sponsor | May 09, 2023 |
| Draft recommendation posted for stakeholder feedback | May 18, 2023 |
| End of feedback period | June 02, 2023 |
Files
Last Updated : May 18, 2023